CURE:NYE-Direxion Daily Healthcare Bull 3X Shares (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 131.09

Change

-2.09 (-1.57)%

Market Cap

USD 0.19B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes domestic companies from the healthcare sector, which includes: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and etc. It is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B..

-2.85 (-7.77%)

USD 12.27B
QLD ProShares Ultra QQQ

-2.85 (-2.83%)

USD 7.32B
FNGU MicroSectors FANG+ Index 3X Le..

-20.41 (-4.98%)

USD 5.28B
SSO ProShares Ultra S&P500

-1.68 (-1.86%)

USD 5.17B
UPRO ProShares UltraPro S&P500

-2.39 (-2.77%)

USD 4.05B
TECL Direxion Daily Technology Bull..

-6.28 (-7.17%)

USD 3.28B
USD ProShares Ultra Semiconductors

-8.18 (-6.82%)

USD 1.18B
YINN Direxion Daily FTSE China Bull..

+4.52 (+12.24%)

USD 1.15B
LABU Direxion Daily S&P Biotech Bul..

-3.49 (-2.71%)

USD 0.94B
DPST Direxion Daily Regional Banks ..

-9.72 (-9.77%)

USD 0.80B

ETFs Containing CURE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.85% 64% D 90% A-
Dividend Return 0.94% 46% F 16% F
Total Return 29.79% 62% D 89% A-
Trailing 12 Months  
Capital Gain 53.02% 41% F 90% A-
Dividend Return 1.79% 49% F 24% F
Total Return 54.81% 41% F 90% A-
Trailing 5 Years  
Capital Gain 171.63% 85% B 92% A
Dividend Return 6.91% 84% B 20% F
Total Return 178.54% 85% B 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 21.60% N/A N/A 84% B
Dividend Return 22.20% N/A N/A 82% B
Total Return 0.60% N/A N/A 14% F
Risk Return Profile  
Volatility (Standard Deviation) 40.39% N/A N/A 23% F
Risk Adjusted Return 54.97% N/A N/A 71% C-
Market Capitalization 0.19B 59% D- 35% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike